Preventing Marrow Transplantation

Do you think this patient would have been cured .. IF .. they had
removed the iron .. FIRST .. without ever HAVING to do a marrow
transplantation .. ?

The second article shows .. in anemia .. BY doing JUST that they
accidentally / paradoxically .. **cured** .. that is .. **cured**
the .. patient.

"unexpected reduction in blood transfusion requirement, ultimately
resulting in long-lasting
transfusion-free survival. "

**Cured**

Hemoglobin. 2006;30(1):131-7. Links
Iron burden and liver fibrosis decrease during a long-term phlebotomy
program and iron chelating treatment after bone marrow
transplantation.
Meo A, Ruggeri A, La Rosa MA, Zanghì L, Morabito N, Duca L.
Paediatric Department, "G. Martino" Policlinico University of Messina,
Messina, Italy. ameo@unime.it

In this retrospective study, we report the results of the association
of a combined phlebotomy program and chelation in hereditary
sideroblastic anemia (HSA) to reduce iron overload after bone marrow
transplantation (BMT). A male HSA patient, not responding to
pyridoxine treatment, was submitted to successful allogeneic BMT. As
there was a persistence of a tissue iron overload, a regular
phlebotomy program was started followed by chelation. A significant
decrease of iron burden was obtained using a combined treatment with
deferoxamine (DFO) and deferiprone (L1) in addition to the phlebotomy
program. A 10-year follow-up shows a marked decrease in the
concentration of serum ferritin, non-transferrin-bound iron (NTBI),
liver iron and normal hemoglobin (Hb), which allows the patient to
reach and maintain a good quality of life.

PMID: 16540426 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------

<<snip>>
resulting in long-lasting transfusion-free survival
<<snip>>

Correction of anemia in a transfusion-dependent patient with primary
myelofibrosis receiving iron chelation therapy with deferasirox
(Exjade®, ICL670)
Authors: Di Tucci, Anna Angela1; Murru, Roberta1; Alberti, Daniele2;
Rabault, Bertrand2; Deplano, Simona1; Angelucci, Emanuele1


Source: European Journal of Haematology, Volume 78, Number 6, June
2007, pp. 540-542(3)


Publisher: Blackwell Publishing
Abstract:


Transfusional iron overload in patients with chronic anemias can
result in multiple organ failure. Experience in the management of
iron
overload in patients with myelodysplastic syndromes is limited, as
many do not receive chelation therapy due to short-life expectancy
and
the difficulties associated with the administration of the current
reference standard chelator, deferoxamine. There have, however, been
some reports of reduced transfusion requirement associated with
chelation therapy in patients with myelodysplastic syndromes and
myelofibrosis. Here, we discuss a patient with primary myelofibrosis
and related transfusion-dependent anemia who received chelation
therapy with the once-daily oral iron chelator, deferasirox. In
addition to the reduced iron levels, the patient demonstrated an
unexpected reduction in blood transfusion requirement, ultimately
resulting in long-lasting transfusion-free survival.
Keywords: myelofibrosis; iron overload; chelation


Document Type: Research article


DOI: 10.1111/j.1600-0609.2007.00840.x


Affiliations: 1: Unità Operativa Ematologia e Centro Trapianti
Midollo
Osseo, Ospedale Oncologico `Armando Businco', Cagliari, Italy 2:
Novartis Pharma AG, Basel, Switzerland


Who loves ya.
Tom


Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com


Man Is A Herbivore!
http://tinyurl.com/a3cc3


DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk